These findings may provide insights into the lower overall response rates in OC patients treated with anti-PD-L1 therapy compared to other types of cancer, with the response rates of pembrolizumab and nivolumab being 11.5% and 15%, respectively [6, 71]. The gene discussed is CD274; the disease is cancer.